PureHealth Holding PJSC (ADX: PUREHEALTH), the largest healthcare group in the Middle East, has announced shareholder approval for its first-ever dividend since listing on the Abu Dhabi Securities Exchange (ADX) in December 2023. The announcement came following the Group’s Annual General Assembly (AGM), marking a significant milestone in its journey as a publicly listed company.
Strong Financial Year Ends with Shareholder Reward
The approved final dividend for the 2024 financial year totals AED 343 million, equivalent to 3.09 fils per share, and represents 20% of the Group’s net profit. This decision reflects PureHealth’s robust financial performance and commitment to shareholder value.
CEO Shaista Asif stated:
“Following a transformative 2024, marked by strategic growth and innovation, this dividend underlines PureHealth’s ability to deliver strong returns while maintaining momentum in global expansion and operational excellence.”
Solid Financial Position Supports Ambitious Growth
PureHealth ended the 2024 financial year with exceptional results:
- Revenues: AED 25.8 billion
- EBITDA: AED 4.1 billion
- Net Profit: AED 1.7 billion
- Cash Reserves: AED 11.9 billion
- Leverage Ratio: ~0.1x
This solid financial footing gives the Group significant strategic flexibility to pursue growth initiatives, including further acquisitions and global expansion.
Strategic Expansion: Hellenic Healthcare Deal
As part of its international growth strategy, PureHealth recently completed the acquisition of a 60% stake in Hellenic Healthcare Group from private equity firm CVC. CVC will continue as a minority shareholder, partnering with PureHealth to drive performance in the acquired entity.
Dividend Distribution Timeline
| Event | Date |
|---|---|
| AGM Approval | 9 April 2025 |
| Last Day to Purchase (Entitlement Date) | 17 April 2025 |
| Ex-Dividend Date | 18 April 2025 |
| Record Date | 21 April 2025 |
| Dividend Payment Date | 08 May 2025 |
Future Outlook
With a stable financial base, low leverage, and a growing international footprint, PureHealth remains well-positioned to lead innovation in the healthcare sector. The approved dividend signals the Group’s confidence in its long-term vision and commitment to delivering continued value to shareholders.
